Satisfaction and Quality of Life After Switching from Pills to HIV Injections
Studies satisfaction and quality of life in adults with HIV switching to injections.
Plain-language title generated from the registry record
Registry title: Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine
Key facts
- Where
- Santiago, ChileSee the site
Where in Chile
- CICUCSantiago, ChileNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pontificia Universidad Catolica de Chile
- Trial code
- NCT05835635
- Record updated
- 7 November 2024
- Original description
This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.Read full original descriptionShow less
Level of Satisfaction and Quality of Life in People Living With HIV in Chile, Who Switch From Oral Therapy to Long-acting Injectable Cabotegravir + Rilpivirine
This protocol will assess the level of satisfaction, acceptance of treatment and quality of life of patients with undetectable HIV who voluntarily change from oral to injectable antiretroviral treatment at 72 weeks of follow-up.
Inclusion: All patients who, according to the recommendations for use, can receive LA- injectable Cabotegravir +Rilpivirine therapy will be invited to participate in the study; Recommendations for use:; HIV-1 positive patients, on antiretroviral therapy; Older than 18 years of age at the time of signing the informed consent; Undetectable HIV viral load in the last 6 months; Willing to switch from oral to injectable therapy.
Exclusion: These criteria are defined for those patients who, according to the recommendations for use, cannot receive the therapy:; Previous virological failure; Concomitant use with: rifampin, carbamazepine, oxcarbazepine, phenytoin and phenobarbital or any contraindication to one of the drugs of the study; Patients with decompensated pathology (physical or mental) or active opportunistic infection at the time of admission; Known hepatitis B co-infection; Any evidence of primary resistance or the presence of any major known INI or NNRTI resistance-associated mutation by any historical resistance test result; Pregnancy (There is insufficient data for people who become pregnant on CAB or those planning to conceive because available pregnancy PK data are limited (n = 3), and data on clinical outcomes in pregnancy are extremely limited. Therefore, CAB is Not Recommended for pregnant or nonpregnant people initiating or restarting ART or for those whose current regimen is not well tolerated and/or not fully suppressive).